{"ticker": {"uuid": "97b1b519-5a66-4b2a-914c-5db339fee3a1", "symbol": "MNPR", "name": "Monopar Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Monopar: A Rare Disease Asset With Heavy-Metal Upside (Initiating Buy)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQVHBWTTZkZnliM1YzSDRNRXJYS1kxdUdvckFkQXA0dC05RnF4SkU2Z0dqcXZZNFl2SUtKdGVGQlhEblA4WW1XTy1NWDlrck9LYWlkUmxnYUNpaS00MmZ0OEIwb2VtT2k5aC1SWU54dkVJRkRua2VpVkRiRHM5UjM0ZUtGRkFKS3VKWUZSU0NfQ0ZpcENKTkRESV85RU1RTDEzVmxMZFd1SGZ1NjF6?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-17T07:58:35+00:00", "published_display": "17 Jul 2026 07:58", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cantor Fitzgerald reiterates Monopar stock Overweight rating at $109 By Investing.com", "summary": "Cantor Fitzgerald has reiterated an Overweight rating and a $109 price target for Monopar Therapeutics (NASDAQ:MNPR), ahead of an expected New Drug Application submission for ALXN1840 for Wilson disease. The firm highlighted Monopar's significant stock return and upward earnings ", "url": "https://m.za.investing.com/news/stock-market-news/cantor-fitzgerald-reiterates-monopar-stock-overweight-rating-at-109-93CH-4370285?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-15T22:11:48", "published_display": "15 Jul 2026 22:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Monopar Therapeutics Inc \u2013 DUS:1IY0", "summary": "This article displays the \"Price to sales forward\" financial metric for Monopar Therapeutics Inc (DUS:1IY0) on the TradingView platform. It shows that there are no recorded trades for the period and highlights data sources like ICE Data Services and FactSet. The content primarily", "url": "https://www.tradingview.com/symbols/DUS-1IY0/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T03:42:31", "published_display": "14 Jul 2026 03:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "(MNPR) Movement as an Input in Quant Signal Sets", "summary": "This article analyzes Monopar Therapeutics Inc. (NASDAQ: MNPR) using AI-driven quantitative signals. It highlights strong sentiment across all horizons supporting an overweight bias and details three institutional trading strategies: Position Trading, Momentum Breakout, and Risk ", "url": "https://news.stocktradersdaily.com/news_release/16/MNPR_Movement_as_an_Input_in_Quant_Signal_Sets_071326085001_1783947001.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T08:50:00", "published_display": "13 Jul 2026 08:50", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Stocks At 52-Week Highs: TRAX, BBIO, MNPR, TXG, MPLT", "summary": "Several biotech companies, including First Tracks Biotherapeutics (TRAX), BridgeBio Pharma (BBIO), Monopar Therapeutics (MNPR), 10x Genomics (TXG), and MapLight Therapeutics (MPLT), reached 52-week highs on July 9, 2026. These gains were propelled by positive developments such as", "url": "https://www.rttnews.com/3666058/biotech-stocks-at-52-week-highs-trax-bbio-mnpr-txg-mplt.aspx", "source_name": "RTTNews", "published_at": "2026-07-11T07:39:31", "published_display": "11 Jul 2026 07:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MNPR (MNPR): Arthur Klausner files Form 144/A to sell 5,000 shares", "summary": "Arthur Klausner has filed a Form 144/A indicating his intent to sell up to 5,000 common shares of Monopar Therapeutics (MNPR) through MLPFS on NASDAQ, effective on or after July 8, 2026. These shares originated from restricted stock unit vestings between 2020 and 2023 as part of ", "url": "https://www.stocktitan.net/sec-filings/MNPR/144-a-monopar-therapeutics-sec-filing-f217b7553a63.html", "source_name": "Stock Titan", "published_at": "2026-07-10T21:39:59", "published_display": "10 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Monopar Therapeutics SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxObmR2QXRYTHRFcmNpVlhtcWlldVN2UXRjeFp6bF9Db1F2cExyeTZ3eDBQWlpCLVVvODIyRVZzMnV4azBQNWtKRFN2clE5NXFIWmxydmVrQ3hQSHRTX2JxdV96ZGI5alFnSGR5ZXJ0cTJJdUhfV3BNMHllNENFZTA4dHdFazhYNUZ1dXRPcnUzeVpMc0Q3WDA4WWFsYjlYdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T18:29:25+00:00", "published_display": "07 Jul 2026 18:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MNPR stock. Monopar Therapeutics stays tied to its clinical pipeline.", "summary": "Monopar Therapeutics Inc. (MNPR) is a small-cap clinical-stage biotechnology company listed on Nasdaq, with its valuation closely linked to its development-stage pipeline. The company focuses on developing therapies for oncology and rare diseases, with its lead program, ALXN1840,", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/mnpr-stock-monopar-therapeutics-stays-tied-to-its-clinical-pipeline/69716147", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T17:01:22", "published_display": "07 Jul 2026 17:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Therapeutics SEC Filing", "summary": "This article reports on Monopar Therapeutics' SEC Form 144 filing, which details a proposed sale of 5,000 shares of Class A securities by Arthur Klausner on July 7, 2026, with an aggregate market value of $485,250. The filing indicates the securities were acquired on August 13, 2", "url": "https://www.stocktitan.net/sec-filings/MNPR/144-monopar-therapeutics-sec-filing-2f9af38e6e32.html", "source_name": "Stock Titan", "published_at": "2026-07-07T02:28:00", "published_display": "07 Jul 2026 02:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Monopar Therapeutics Inc. \u2013 NASDAQ:MNPR", "summary": "The article focuses on the enterprise value to EBIT forward ratio for Monopar Therapeutics Inc. (NASDAQ: MNPR), presenting financial data for the company. It appears to be a financial data point or metric displayed within the TradingView platform, without additional commentary or", "url": "https://www.tradingview.com/symbols/NASDAQ-MNPR/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T17:09:45", "published_display": "04 Jul 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Monopar Therapeutics Inc For: 2 July By Investing.com", "summary": "This article from Investing.com announces the filing of Form 4 for Monopar Therapeutics Inc., dated July 2nd. It briefly mentions the company's stock symbol MNPR and its share price performance on that day. The article is primarily a placeholder for the SEC filing announcement.", "url": "https://ng.investing.com/news/stock-market-news/form-4-monopar-therapeutics-inc-for-2-july-93CH-2585457", "source_name": "Investing.com Nigeria", "published_at": "2026-07-03T17:09:45", "published_display": "03 Jul 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Therapeutics: ALXN1840's Bull Case Has Improved (NASDAQ:MNPR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOZHkySEY3SUJsb0daWndldU1uZUtGdFpNQm95a0hxMUZfLWFUZTZCVVNMcDFuNERNamxwSm5KdDR2dklqbWF6R3hocVl2Q1l6cHNwS21WU0hsaHJqU0VncWZJLTNURWxkTWJvRDU5U1BQcmUyQ3hIYW82MnNQMlJQd0owOGhTNXhPbVBnelRWVVRhcDZ2N3hUZA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Therapeutics (MNPR) CFO nets shares from RSU vesting and tax withholding", "summary": "Monopar Therapeutics' CFO, Vu Quan Anh, reported routine equity compensation activity involving restricted stock units (RSUs). On June 30, 2026, 1,228 RSUs vested, converting to common shares, with 507 shares withheld by the company for tax obligations. Following these transactio", "url": "https://www.stocktitan.net/sec-filings/MNPR/form-4-monopar-therapeutics-insider-trading-activity-7542fbced6d8.html", "source_name": "Stock Titan", "published_at": "2026-07-02T23:09:33", "published_display": "02 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Therapeutics (MNPR) CEO nets shares after RSU vesting and tax withholding", "summary": "Monopar Therapeutics CEO Chandler Robinson had 12,873 restricted stock units vest into common shares on June 30, 2026. To cover tax obligations, 4,084 shares were withheld by the issuer at $92.59 per share. Following these transactions, Robinson directly holds 99,267 shares and i", "url": "https://www.stocktitan.net/sec-filings/MNPR/form-4-monopar-therapeutics-insider-trading-activity-009df400aa17.html", "source_name": "Stock Titan", "published_at": "2026-07-02T23:09:33", "published_display": "02 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Therapeutics (MNPR) COO gains stock via RSU vesting and tax withholding", "summary": "Monopar Therapeutics COO Andrew Cittadine converted 5,254 restricted stock units (RSUs) into common stock on June 30, 2026, with 2,309 shares withheld by the company for tax purposes. Following these routine transactions, Cittadine directly holds 57,923 shares of Monopar common s", "url": "https://www.stocktitan.net/sec-filings/MNPR/form-4-monopar-therapeutics-insider-trading-activity-8bfb63c4ea75.html", "source_name": "Stock Titan", "published_at": "2026-07-02T23:09:33", "published_display": "02 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liquidity Mapping Around (MNPR) Price Events", "summary": "This article provides a liquidity mapping analysis for Monopar Therapeutics Inc. (NASDAQ: MNPR), highlighting strong sentiment across all time horizons. It details several AI-generated trading strategies including position, momentum breakout, and risk hedging, along with multi-ti", "url": "https://news.stocktradersdaily.com/news_release/20/Liquidity_Mapping_Around_MNPR_Price_Events_070226074202_1782992522.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-02T07:41:00", "published_display": "02 Jul 2026 07:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Therapeutics (MNPR) director Nicole Sweeny files initial Form 3", "summary": "Monopar Therapeutics director Nicole Sweeny has filed an initial Statement of Beneficial Ownership on Form 3, establishing her as an insider of the company. This filing, accepted by the SEC on June 30, 2026, indicates her role as a director but does not report any stock transacti", "url": "https://www.stocktitan.net/sec-filings/MNPR/form-3-monopar-therapeutics-initial-statement-of-beneficial-ownership-fb4befdac773.html", "source_name": "Stock Titan", "published_at": "2026-07-01T03:10:06", "published_display": "01 Jul 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Monopar Therapeutics Inc For: 30 June By Investing.com", "summary": "This article announces the filing of Form 4 for Monopar Therapeutics Inc. for the period ending June 30th. It is a brief news item from Investing.com, accompanied by current market data for various indices, commodities, and stocks. The company's stock symbol MNPR is noted with a ", "url": "https://ca.investing.com/news/stock-market-news/form-4-monopar-therapeutics-inc-for-30-june-93CH-4714838", "source_name": "Investing.com Canada", "published_at": "2026-07-01T03:04:06", "published_display": "01 Jul 2026 03:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Therapeutics Says ALXN1840 Receives FDA Rare Pediatric Disease Designation in Wilson Disease", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/monopar-therapeutics-says-alxn1840-receives-133303492.html", "source_name": "MT Newswires", "published_at": "2026-06-30T13:33:03+00:00", "published_display": "30 Jun 2026 13:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease", "summary": "Monopar Therapeutics announced that the FDA granted Rare Pediatric Disease (RPD) designation to ALXN1840 for Wilson disease. This designation could lead to a pediatric Priority Review Voucher upon NDA approval, expediting the review process for future marketing applications. ALXN", "url": "https://www.manilatimes.net/2026/06/30/tmt-newswire/globenewswire/monopar-therapeutics-receives-fda-rare-pediatric-disease-designation-for-alxn1840-for-the-treatment-of-wilson-disease/2375713/amp", "source_name": "The Manila Times", "published_at": "2026-06-30T12:10:06", "published_display": "30 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA rare pediatric disease tag could speed ALXN1840\u2019s path for Wilson disease", "summary": "Monopar Therapeutics announced that its late-stage candidate ALXN1840 for Wilson disease has received Rare Pediatric Disease (RPD) designation from the FDA. This designation makes Monopar eligible for a potential pediatric Priority Review Voucher upon NDA approval, which could ex", "url": "https://www.stocktitan.net/news/MNPR/monopar-therapeutics-receives-fda-rare-pediatric-disease-designation-7c6xk6filuea.html", "source_name": "Stock Titan", "published_at": "2026-06-30T12:09:07", "published_display": "30 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA grants Rare Pediatric Disease designation to Monopar (MNPR) Wilson disease drug ALXN1840", "summary": "Monopar Therapeutics (MNPR) announced that the FDA has granted Rare Pediatric Disease (RPD) designation to its late-stage drug candidate, ALXN1840, for the treatment of Wilson disease. This designation could provide Monopar with a pediatric Priority Review Voucher upon ALXN1840's", "url": "https://www.stocktitan.net/sec-filings/MNPR/8-k-monopar-therapeutics-reports-material-event-3ef9e67c0969.html", "source_name": "Stock Titan", "published_at": "2026-06-30T12:09:07", "published_display": "30 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Therapeutics (MNPR) director granted 1,284 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQei1vOS11d05ldzd1VXRrcjVZanlTOHFHdmlua1dZc2lnWmEtc2pjclFVOU9TMFM1VGg4Z2d5ZUVBajRXTS1VNGJyUElhb2xaQUg0aWtjaFJEYVJxWXJvUTFkWll5eEE0ZlJUN1VvR2hGOUxYLTA5TWpYOFUtOGliVUUzbHRzbFFQMk05M0lPLS1WZjBDNVZiR3VaaVh2dzB2c19OQ1djZlJGZkRSSW1Ta0h5VXg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Monopar Therapeutics Inc. \u2013 NASDAQ:MNPR", "summary": "This article provides the \"Price to book forward\" metric for Monopar Therapeutics Inc. (NASDAQ: MNPR). It is a finance-related page from TradingView, focusing on the company's financial data.", "url": "https://www.tradingview.com/symbols/NASDAQ-MNPR/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T15:41:00", "published_display": "29 Jun 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Therapeutics Inc.(NasdaqCM: MNPR) added to Russell 2000 Value Benchmark", "summary": "Monopar Therapeutics Inc. (NasdaqCM:MNPR), a clinical-stage biopharmaceutical company focused on treatments for Wilson disease and radiopharmaceuticals for oncology, has been added to the Russell 2000 Value Benchmark. The company's stock experienced a significant 7.85% increase, ", "url": "https://www.marketscreener.com/news/monopar-therapeutics-inc-nasdaqcm-mnpr-added-to-russell-2000-value-benchmark-ce7f5fdfd88bfe23", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T15:40:15", "published_display": "29 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Therapeutics Inc.(NasdaqCM:MNPR) added to Russell Microcap Value Benchmark Index", "summary": "Monopar Therapeutics Inc. (NasdaqCM:MNPR) has been added to the Russell Microcap Value Benchmark Index. The clinical-stage biopharmaceutical company focuses on treatments for Wilson disease and developing novel radiopharmaceuticals for oncology. This inclusion in the Russell", "url": "https://www.marketscreener.com/news/monopar-therapeutics-inc-nasdaqcm-mnpr-added-to-russell-microcap-value-benchmark-index-ce7f5fdfd989f32c", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T13:40:15", "published_display": "29 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Therapeutics Insiders Make Handsome Sum Selling Stock At US$67.15 Per Share", "summary": "Monopar Therapeutics' stock recently rose 28%, but insiders who sold shares in the last year missed out on higher valuations. While the biggest insider sale by Arthur Klausner was for US$344k at US$68.09 per share, below the current price of US$87.68, insiders still own 7.0% of t", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnpr/monopar-therapeutics/news/monopar-therapeutics-insiders-make-handsome-sum-selling-stoc", "source_name": "Simply Wall Street", "published_at": "2026-06-29T10:40:14", "published_display": "29 Jun 2026 10:40", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Monopar Therapeutics Inc. \u2013 NASDAQ:MNPR", "summary": "This page from TradingView provides a financial overview of Monopar Therapeutics Inc. (NASDAQ: MNPR), specifically focusing on its forward price-to-earnings ratio. It indicates that the market was closed at the time of viewing, with no trades occurring. The content is primarily a", "url": "https://www.tradingview.com/symbols/NASDAQ-MNPR/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T05:40:15", "published_display": "29 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Monopar Therapeutics Inc \u2013 GETTEX:1IY0", "summary": "This article briefly presents a financial metric, \"Price to book forward,\" for Monopar Therapeutics Inc (GETTEX:1IY0). The content indicates that market data and reference data are provided by ICE Data Services and FactSet, respectively. The page appears to be a financial data sn", "url": "https://www.tradingview.com/symbols/GETTEX-1IY0/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T00:40:15", "published_display": "29 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Monopar Therapeutics Inc. \u2013 NASDAQ:MNPR", "summary": "This article displays financial data for Monopar Therapeutics Inc. (NASDAQ: MNPR), specifically its enterprise value to EBITDA forward. It indicates that the market was closed with no trades at the time of publication. The content also notes that this information is provided by F", "url": "https://www.tradingview.com/symbols/NASDAQ-MNPR/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T14:10:45", "published_display": "28 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Monopar Therapeutics Inc \u2013 GETTEX:1IY0", "summary": "The article provides financial data for Monopar Therapeutics Inc (GETTEX:1IY0), specifically its enterprise value to EBITDA forward. It notes that the market is currently closed with no trades. The information is presented on a TradingView page, including an overview of financial", "url": "https://www.tradingview.com/symbols/GETTEX-1IY0/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T10:09:53", "published_display": "28 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Monopar Therapeutics Inc. \u2013 NASDAQ:MNPR", "summary": "This article provides financial information for Monopar Therapeutics Inc. (NASDAQ: MNPR), specifically its enterprise value to revenue forward. It is presented in the context of TradingView, a financial platform offering various market data and analysis tools. The content include", "url": "https://www.tradingview.com/symbols/NASDAQ-MNPR/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T07:09:53", "published_display": "28 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/monopar-presents-analyses-phase-3-200500137.html", "source_name": "GlobeNewswire", "published_at": "2026-06-26T20:05:00+00:00", "published_display": "26 Jun 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Shareholders Approve Directors, Pay and Incentive Plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxPSUYyM3RTcWdQQUZHRDkzQ3ZzVGh6NmQ2eFhJOE1zRGw2WXA5cHpJeG9BLURDdUF5M1V2bkppTDB1NUZpSlF6Y0h3T28wVWhlcG51TFl1RmlGOHNBOGJSeEdBcEJKNy01RDBsbWYxTU45THdiY1cwNzhaaWJZSmdSUVBGRlUzNEh1alFfcXhmaUltSklISmxqZExqV3JvUjZ2OWotQ1B6VVFtM1ZaM2hBSjZDbjExd2RFME1fNUlnQXg5d0phUDlyWDN1UGduNTFTcWJKQlc4T1Zrdw?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar (NASDAQ: MNPR) meeting backs board, pay and 2026 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPNWYzamswY1FSYXRMTWtIdlFUbE1ZWGhIZDhxX0dkUFh6cllPZnhXUExlRXN3b1VCSUJaSG81ajd1SElpVEFmTV9HSll4dzVKQXNJRXd2ay1qWEhYS3duelI5MUtIZDg4UDNlTnU5MUx0bHVGT0pNX21iaVp0bmQtYVdsQXBoMldGZEtmUVJBNWFYY0xqZlpNZTJ2VExjUUhqSXZDX0ctZS1SNWNtbmc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Believe Monopar Therapeutics (MNPR) Could Rally 88.92%: Here's is How to Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQazhHbUNWQ3pYZ2RkVzNmMHJWenZMUURsZGFIT0tGWHplX2hMY3huYlFydXBYcXAwQTZ0d1IwZnl0LU5TTVgybnd1M3RaRG5lZWd0VW0xS0V4NDk0UHFsS0p0VTI1MDIzS1lkejNYaUhBS2JCc3JmQTRLdTVpZ2Q5ODRKMnVuLWpydFYyOHhvcTY1RHV3UEhPaFVscGpYc3lSaTcw?oc=5", "source_name": "Market source", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/monopar-presents-phase-2-alxn1840-110000996.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T11:00:00+00:00", "published_display": "01 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Therapeutics (MNPR) shares Phase 2 Wilson disease data at EASL 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPZG91VEdqQVFJT2FzRk1DWEVmb1RxM2l6RkpzckViNnJNSm8xSExLb3kzQXVHUDBwOUZuMlI1TGpHMVU2aTRfblJfZzN0UW93UXp6WUhxR1JZdzR2bG5UeTBDRlZqeHJMTmpFZDNncE52blllOGdMQzA1Mi11Rk9pU2lsVXFRX2tEaDZxVnJ4UURfTU41UEZ0NzBZbVdIQzdyZkVDenAyYkN3Q0dHRUE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Reports Publication of Phase 2 ALXN1840 Trial Data in Wilson Disease", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/monopar-reports-publication-phase-2-215737651.html", "source_name": "MT Newswires", "published_at": "2026-05-19T21:57:37+00:00", "published_display": "19 May 2026 21:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/monopar-announces-publication-phase-2-213300471.html", "source_name": "GlobeNewswire", "published_at": "2026-05-19T21:33:00+00:00", "published_display": "19 May 2026 21:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/monopar-therapeutics-reports-first-quarter-180000306.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T18:00:00+00:00", "published_display": "14 May 2026 18:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Here's Why We're Not Too Worried About Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOTV8wOFJ5eHFESG5Qd05OQWtFd3dWVTJJWlRMU3Z6THJWMVhZSllZYkhrOHJrS1Itd2tjejBkUXhzbWs4RWVFVXEtZ2dBU24ya1lTTEh0a0h2UDNRWi1OWDhXUWRLUXAzX2FrWUpZaDhiWDM4eTFaQVpZSGhranNxclpWYlJmSFppN3JRSHE2ZlJ0bFUyNUVtcHhZY3BOWDJ6YWp0Qw?oc=5", "source_name": "Market source", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/monopar-presents-phase-3-data-230000865.html", "source_name": "GlobeNewswire", "published_at": "2026-04-19T23:00:00+00:00", "published_display": "19 Apr 2026 23:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Monopar Therapeutics Inc. Reports Q4 and Full-Year 2025 Financial Results and Highlights Progress for ALXN1840 in Wilson Disease | MNPR Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxPS2ZmcF9tNXlOb0xNWUtCMkZQSjVzUUlNWEhYUXpucm9ScWpESlBKNDFkRzhhX0pjQWJkTVU5UHVuT1dMYzBNclhpOUJIc3ZtUDNWV2dhaXpvZG1FRUNpTVBvSWxuWExDV3VBMFhPN3JBTHF1R2lrMXdjdnlraDE2SkNBUC01M2s0OVpzd2RRZWpZY3F4aVlCbk1yMEM0RFNHZkZnSkh6Rm5iRlllZ0VrX3FQdzVKbnB2a1lGQ0FXd1N4TEtqYnZSZWtGczNfNEZ0aGZUcnpPRTljS3JOcGwyeWM1ZkRLX1B4U2haM0FHLXlsWDQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Monopar: A Rare Disease Asset With Heavy-Metal Upside (Initiating Buy)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQVHBWTTZkZnliM1YzSDRNRXJYS1kxdUdvckFkQXA0dC05RnF4SkU2Z0dqcXZZNFl2SUtKdGVGQlhEblA4WW1XTy1NWDlrck9LYWlkUmxnYUNpaS00MmZ0OEIwb2VtT2k5aC1SWU54dkVJRkRua2VpVkRiRHM5UjM0ZUtGRkFKS3VKWUZSU0NfQ0ZpcENKTkRESV85RU1RTDEzVmxMZFd1SGZ1NjF6?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-17T07:58:35+00:00", "published_display": "17 Jul 2026 07:58", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald reiterates Monopar stock Overweight rating at $109 By Investing.com", "summary": "Cantor Fitzgerald has reiterated an Overweight rating and a $109 price target for Monopar Therapeutics (NASDAQ:MNPR), ahead of an expected New Drug Application submission for ALXN1840 for Wilson disease. The firm highlighted Monopar's significant stock return and upward earnings ", "url": "https://m.za.investing.com/news/stock-market-news/cantor-fitzgerald-reiterates-monopar-stock-overweight-rating-at-109-93CH-4370285?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-15T22:11:48", "published_display": "15 Jul 2026 22:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Monopar Therapeutics Inc \u2013 DUS:1IY0", "summary": "This article displays the \"Price to sales forward\" financial metric for Monopar Therapeutics Inc (DUS:1IY0) on the TradingView platform. It shows that there are no recorded trades for the period and highlights data sources like ICE Data Services and FactSet. The content primarily", "url": "https://www.tradingview.com/symbols/DUS-1IY0/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T03:42:31", "published_display": "14 Jul 2026 03:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(MNPR) Movement as an Input in Quant Signal Sets", "summary": "This article analyzes Monopar Therapeutics Inc. (NASDAQ: MNPR) using AI-driven quantitative signals. It highlights strong sentiment across all horizons supporting an overweight bias and details three institutional trading strategies: Position Trading, Momentum Breakout, and Risk ", "url": "https://news.stocktradersdaily.com/news_release/16/MNPR_Movement_as_an_Input_in_Quant_Signal_Sets_071326085001_1783947001.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T08:50:00", "published_display": "13 Jul 2026 08:50", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Stocks At 52-Week Highs: TRAX, BBIO, MNPR, TXG, MPLT", "summary": "Several biotech companies, including First Tracks Biotherapeutics (TRAX), BridgeBio Pharma (BBIO), Monopar Therapeutics (MNPR), 10x Genomics (TXG), and MapLight Therapeutics (MPLT), reached 52-week highs on July 9, 2026. These gains were propelled by positive developments such as", "url": "https://www.rttnews.com/3666058/biotech-stocks-at-52-week-highs-trax-bbio-mnpr-txg-mplt.aspx", "source_name": "RTTNews", "published_at": "2026-07-11T07:39:31", "published_display": "11 Jul 2026 07:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MNPR (MNPR): Arthur Klausner files Form 144/A to sell 5,000 shares", "summary": "Arthur Klausner has filed a Form 144/A indicating his intent to sell up to 5,000 common shares of Monopar Therapeutics (MNPR) through MLPFS on NASDAQ, effective on or after July 8, 2026. These shares originated from restricted stock unit vestings between 2020 and 2023 as part of ", "url": "https://www.stocktitan.net/sec-filings/MNPR/144-a-monopar-therapeutics-sec-filing-f217b7553a63.html", "source_name": "Stock Titan", "published_at": "2026-07-10T21:39:59", "published_display": "10 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Monopar Therapeutics SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxObmR2QXRYTHRFcmNpVlhtcWlldVN2UXRjeFp6bF9Db1F2cExyeTZ3eDBQWlpCLVVvODIyRVZzMnV4azBQNWtKRFN2clE5NXFIWmxydmVrQ3hQSHRTX2JxdV96ZGI5alFnSGR5ZXJ0cTJJdUhfV3BNMHllNENFZTA4dHdFazhYNUZ1dXRPcnUzeVpMc0Q3WDA4WWFsYjlYdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T18:29:25+00:00", "published_display": "07 Jul 2026 18:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MNPR stock. Monopar Therapeutics stays tied to its clinical pipeline.", "summary": "Monopar Therapeutics Inc. (MNPR) is a small-cap clinical-stage biotechnology company listed on Nasdaq, with its valuation closely linked to its development-stage pipeline. The company focuses on developing therapies for oncology and rare diseases, with its lead program, ALXN1840,", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/mnpr-stock-monopar-therapeutics-stays-tied-to-its-clinical-pipeline/69716147", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T17:01:22", "published_display": "07 Jul 2026 17:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Therapeutics SEC Filing", "summary": "This article reports on Monopar Therapeutics' SEC Form 144 filing, which details a proposed sale of 5,000 shares of Class A securities by Arthur Klausner on July 7, 2026, with an aggregate market value of $485,250. The filing indicates the securities were acquired on August 13, 2", "url": "https://www.stocktitan.net/sec-filings/MNPR/144-monopar-therapeutics-sec-filing-2f9af38e6e32.html", "source_name": "Stock Titan", "published_at": "2026-07-07T02:28:00", "published_display": "07 Jul 2026 02:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Monopar Therapeutics Inc. \u2013 NASDAQ:MNPR", "summary": "The article focuses on the enterprise value to EBIT forward ratio for Monopar Therapeutics Inc. (NASDAQ: MNPR), presenting financial data for the company. It appears to be a financial data point or metric displayed within the TradingView platform, without additional commentary or", "url": "https://www.tradingview.com/symbols/NASDAQ-MNPR/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T17:09:45", "published_display": "04 Jul 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Monopar Therapeutics Inc For: 2 July By Investing.com", "summary": "This article from Investing.com announces the filing of Form 4 for Monopar Therapeutics Inc., dated July 2nd. It briefly mentions the company's stock symbol MNPR and its share price performance on that day. The article is primarily a placeholder for the SEC filing announcement.", "url": "https://ng.investing.com/news/stock-market-news/form-4-monopar-therapeutics-inc-for-2-july-93CH-2585457", "source_name": "Investing.com Nigeria", "published_at": "2026-07-03T17:09:45", "published_display": "03 Jul 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Therapeutics: ALXN1840's Bull Case Has Improved (NASDAQ:MNPR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOZHkySEY3SUJsb0daWndldU1uZUtGdFpNQm95a0hxMUZfLWFUZTZCVVNMcDFuNERNamxwSm5KdDR2dklqbWF6R3hocVl2Q1l6cHNwS21WU0hsaHJqU0VncWZJLTNURWxkTWJvRDU5U1BQcmUyQ3hIYW82MnNQMlJQd0owOGhTNXhPbVBnelRWVVRhcDZ2N3hUZA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Therapeutics (MNPR) CFO nets shares from RSU vesting and tax withholding", "summary": "Monopar Therapeutics' CFO, Vu Quan Anh, reported routine equity compensation activity involving restricted stock units (RSUs). On June 30, 2026, 1,228 RSUs vested, converting to common shares, with 507 shares withheld by the company for tax obligations. Following these transactio", "url": "https://www.stocktitan.net/sec-filings/MNPR/form-4-monopar-therapeutics-insider-trading-activity-7542fbced6d8.html", "source_name": "Stock Titan", "published_at": "2026-07-02T23:09:33", "published_display": "02 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Therapeutics (MNPR) CEO nets shares after RSU vesting and tax withholding", "summary": "Monopar Therapeutics CEO Chandler Robinson had 12,873 restricted stock units vest into common shares on June 30, 2026. To cover tax obligations, 4,084 shares were withheld by the issuer at $92.59 per share. Following these transactions, Robinson directly holds 99,267 shares and i", "url": "https://www.stocktitan.net/sec-filings/MNPR/form-4-monopar-therapeutics-insider-trading-activity-009df400aa17.html", "source_name": "Stock Titan", "published_at": "2026-07-02T23:09:33", "published_display": "02 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Therapeutics (MNPR) COO gains stock via RSU vesting and tax withholding", "summary": "Monopar Therapeutics COO Andrew Cittadine converted 5,254 restricted stock units (RSUs) into common stock on June 30, 2026, with 2,309 shares withheld by the company for tax purposes. Following these routine transactions, Cittadine directly holds 57,923 shares of Monopar common s", "url": "https://www.stocktitan.net/sec-filings/MNPR/form-4-monopar-therapeutics-insider-trading-activity-8bfb63c4ea75.html", "source_name": "Stock Titan", "published_at": "2026-07-02T23:09:33", "published_display": "02 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Liquidity Mapping Around (MNPR) Price Events", "summary": "This article provides a liquidity mapping analysis for Monopar Therapeutics Inc. (NASDAQ: MNPR), highlighting strong sentiment across all time horizons. It details several AI-generated trading strategies including position, momentum breakout, and risk hedging, along with multi-ti", "url": "https://news.stocktradersdaily.com/news_release/20/Liquidity_Mapping_Around_MNPR_Price_Events_070226074202_1782992522.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-02T07:41:00", "published_display": "02 Jul 2026 07:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Therapeutics (MNPR) director Nicole Sweeny files initial Form 3", "summary": "Monopar Therapeutics director Nicole Sweeny has filed an initial Statement of Beneficial Ownership on Form 3, establishing her as an insider of the company. This filing, accepted by the SEC on June 30, 2026, indicates her role as a director but does not report any stock transacti", "url": "https://www.stocktitan.net/sec-filings/MNPR/form-3-monopar-therapeutics-initial-statement-of-beneficial-ownership-fb4befdac773.html", "source_name": "Stock Titan", "published_at": "2026-07-01T03:10:06", "published_display": "01 Jul 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Monopar Therapeutics Inc For: 30 June By Investing.com", "summary": "This article announces the filing of Form 4 for Monopar Therapeutics Inc. for the period ending June 30th. It is a brief news item from Investing.com, accompanied by current market data for various indices, commodities, and stocks. The company's stock symbol MNPR is noted with a ", "url": "https://ca.investing.com/news/stock-market-news/form-4-monopar-therapeutics-inc-for-30-june-93CH-4714838", "source_name": "Investing.com Canada", "published_at": "2026-07-01T03:04:06", "published_display": "01 Jul 2026 03:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Therapeutics Says ALXN1840 Receives FDA Rare Pediatric Disease Designation in Wilson Disease", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/monopar-therapeutics-says-alxn1840-receives-133303492.html", "source_name": "MT Newswires", "published_at": "2026-06-30T13:33:03+00:00", "published_display": "30 Jun 2026 13:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease", "summary": "Monopar Therapeutics announced that the FDA granted Rare Pediatric Disease (RPD) designation to ALXN1840 for Wilson disease. This designation could lead to a pediatric Priority Review Voucher upon NDA approval, expediting the review process for future marketing applications. ALXN", "url": "https://www.manilatimes.net/2026/06/30/tmt-newswire/globenewswire/monopar-therapeutics-receives-fda-rare-pediatric-disease-designation-for-alxn1840-for-the-treatment-of-wilson-disease/2375713/amp", "source_name": "The Manila Times", "published_at": "2026-06-30T12:10:06", "published_display": "30 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA rare pediatric disease tag could speed ALXN1840\u2019s path for Wilson disease", "summary": "Monopar Therapeutics announced that its late-stage candidate ALXN1840 for Wilson disease has received Rare Pediatric Disease (RPD) designation from the FDA. This designation makes Monopar eligible for a potential pediatric Priority Review Voucher upon NDA approval, which could ex", "url": "https://www.stocktitan.net/news/MNPR/monopar-therapeutics-receives-fda-rare-pediatric-disease-designation-7c6xk6filuea.html", "source_name": "Stock Titan", "published_at": "2026-06-30T12:09:07", "published_display": "30 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA grants Rare Pediatric Disease designation to Monopar (MNPR) Wilson disease drug ALXN1840", "summary": "Monopar Therapeutics (MNPR) announced that the FDA has granted Rare Pediatric Disease (RPD) designation to its late-stage drug candidate, ALXN1840, for the treatment of Wilson disease. This designation could provide Monopar with a pediatric Priority Review Voucher upon ALXN1840's", "url": "https://www.stocktitan.net/sec-filings/MNPR/8-k-monopar-therapeutics-reports-material-event-3ef9e67c0969.html", "source_name": "Stock Titan", "published_at": "2026-06-30T12:09:07", "published_display": "30 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Therapeutics (MNPR) director granted 1,284 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQei1vOS11d05ldzd1VXRrcjVZanlTOHFHdmlua1dZc2lnWmEtc2pjclFVOU9TMFM1VGg4Z2d5ZUVBajRXTS1VNGJyUElhb2xaQUg0aWtjaFJEYVJxWXJvUTFkWll5eEE0ZlJUN1VvR2hGOUxYLTA5TWpYOFUtOGliVUUzbHRzbFFQMk05M0lPLS1WZjBDNVZiR3VaaVh2dzB2c19OQ1djZlJGZkRSSW1Ta0h5VXg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Monopar Therapeutics Inc. \u2013 NASDAQ:MNPR", "summary": "This article provides the \"Price to book forward\" metric for Monopar Therapeutics Inc. (NASDAQ: MNPR). It is a finance-related page from TradingView, focusing on the company's financial data.", "url": "https://www.tradingview.com/symbols/NASDAQ-MNPR/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T15:41:00", "published_display": "29 Jun 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Therapeutics Inc.(NasdaqCM: MNPR) added to Russell 2000 Value Benchmark", "summary": "Monopar Therapeutics Inc. (NasdaqCM:MNPR), a clinical-stage biopharmaceutical company focused on treatments for Wilson disease and radiopharmaceuticals for oncology, has been added to the Russell 2000 Value Benchmark. The company's stock experienced a significant 7.85% increase, ", "url": "https://www.marketscreener.com/news/monopar-therapeutics-inc-nasdaqcm-mnpr-added-to-russell-2000-value-benchmark-ce7f5fdfd88bfe23", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T15:40:15", "published_display": "29 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Therapeutics Inc.(NasdaqCM:MNPR) added to Russell Microcap Value Benchmark Index", "summary": "Monopar Therapeutics Inc. (NasdaqCM:MNPR) has been added to the Russell Microcap Value Benchmark Index. The clinical-stage biopharmaceutical company focuses on treatments for Wilson disease and developing novel radiopharmaceuticals for oncology. This inclusion in the Russell", "url": "https://www.marketscreener.com/news/monopar-therapeutics-inc-nasdaqcm-mnpr-added-to-russell-microcap-value-benchmark-index-ce7f5fdfd989f32c", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T13:40:15", "published_display": "29 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Therapeutics Insiders Make Handsome Sum Selling Stock At US$67.15 Per Share", "summary": "Monopar Therapeutics' stock recently rose 28%, but insiders who sold shares in the last year missed out on higher valuations. While the biggest insider sale by Arthur Klausner was for US$344k at US$68.09 per share, below the current price of US$87.68, insiders still own 7.0% of t", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnpr/monopar-therapeutics/news/monopar-therapeutics-insiders-make-handsome-sum-selling-stoc", "source_name": "Simply Wall Street", "published_at": "2026-06-29T10:40:14", "published_display": "29 Jun 2026 10:40", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Monopar Therapeutics Inc. \u2013 NASDAQ:MNPR", "summary": "This page from TradingView provides a financial overview of Monopar Therapeutics Inc. (NASDAQ: MNPR), specifically focusing on its forward price-to-earnings ratio. It indicates that the market was closed at the time of viewing, with no trades occurring. The content is primarily a", "url": "https://www.tradingview.com/symbols/NASDAQ-MNPR/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T05:40:15", "published_display": "29 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Monopar Therapeutics Inc \u2013 GETTEX:1IY0", "summary": "This article briefly presents a financial metric, \"Price to book forward,\" for Monopar Therapeutics Inc (GETTEX:1IY0). The content indicates that market data and reference data are provided by ICE Data Services and FactSet, respectively. The page appears to be a financial data sn", "url": "https://www.tradingview.com/symbols/GETTEX-1IY0/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T00:40:15", "published_display": "29 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Monopar Therapeutics Inc. \u2013 NASDAQ:MNPR", "summary": "This article displays financial data for Monopar Therapeutics Inc. (NASDAQ: MNPR), specifically its enterprise value to EBITDA forward. It indicates that the market was closed with no trades at the time of publication. The content also notes that this information is provided by F", "url": "https://www.tradingview.com/symbols/NASDAQ-MNPR/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T14:10:45", "published_display": "28 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Monopar Therapeutics Inc \u2013 GETTEX:1IY0", "summary": "The article provides financial data for Monopar Therapeutics Inc (GETTEX:1IY0), specifically its enterprise value to EBITDA forward. It notes that the market is currently closed with no trades. The information is presented on a TradingView page, including an overview of financial", "url": "https://www.tradingview.com/symbols/GETTEX-1IY0/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T10:09:53", "published_display": "28 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Monopar Therapeutics Inc. \u2013 NASDAQ:MNPR", "summary": "This article provides financial information for Monopar Therapeutics Inc. (NASDAQ: MNPR), specifically its enterprise value to revenue forward. It is presented in the context of TradingView, a financial platform offering various market data and analysis tools. The content include", "url": "https://www.tradingview.com/symbols/NASDAQ-MNPR/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T07:09:53", "published_display": "28 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/monopar-presents-analyses-phase-3-200500137.html", "source_name": "GlobeNewswire", "published_at": "2026-06-26T20:05:00+00:00", "published_display": "26 Jun 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Shareholders Approve Directors, Pay and Incentive Plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxPSUYyM3RTcWdQQUZHRDkzQ3ZzVGh6NmQ2eFhJOE1zRGw2WXA5cHpJeG9BLURDdUF5M1V2bkppTDB1NUZpSlF6Y0h3T28wVWhlcG51TFl1RmlGOHNBOGJSeEdBcEJKNy01RDBsbWYxTU45THdiY1cwNzhaaWJZSmdSUVBGRlUzNEh1alFfcXhmaUltSklISmxqZExqV3JvUjZ2OWotQ1B6VVFtM1ZaM2hBSjZDbjExd2RFME1fNUlnQXg5d0phUDlyWDN1UGduNTFTcWJKQlc4T1Zrdw?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar (NASDAQ: MNPR) meeting backs board, pay and 2026 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPNWYzamswY1FSYXRMTWtIdlFUbE1ZWGhIZDhxX0dkUFh6cllPZnhXUExlRXN3b1VCSUJaSG81ajd1SElpVEFmTV9HSll4dzVKQXNJRXd2ay1qWEhYS3duelI5MUtIZDg4UDNlTnU5MUx0bHVGT0pNX21iaVp0bmQtYVdsQXBoMldGZEtmUVJBNWFYY0xqZlpNZTJ2VExjUUhqSXZDX0ctZS1SNWNtbmc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Believe Monopar Therapeutics (MNPR) Could Rally 88.92%: Here's is How to Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQazhHbUNWQ3pYZ2RkVzNmMHJWenZMUURsZGFIT0tGWHplX2hMY3huYlFydXBYcXAwQTZ0d1IwZnl0LU5TTVgybnd1M3RaRG5lZWd0VW0xS0V4NDk0UHFsS0p0VTI1MDIzS1lkejNYaUhBS2JCc3JmQTRLdTVpZ2Q5ODRKMnVuLWpydFYyOHhvcTY1RHV3UEhPaFVscGpYc3lSaTcw?oc=5", "source_name": "Market source", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/monopar-presents-phase-2-alxn1840-110000996.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T11:00:00+00:00", "published_display": "01 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Therapeutics (MNPR) shares Phase 2 Wilson disease data at EASL 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPZG91VEdqQVFJT2FzRk1DWEVmb1RxM2l6RkpzckViNnJNSm8xSExLb3kzQXVHUDBwOUZuMlI1TGpHMVU2aTRfblJfZzN0UW93UXp6WUhxR1JZdzR2bG5UeTBDRlZqeHJMTmpFZDNncE52blllOGdMQzA1Mi11Rk9pU2lsVXFRX2tEaDZxVnJ4UURfTU41UEZ0NzBZbVdIQzdyZkVDenAyYkN3Q0dHRUE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Reports Publication of Phase 2 ALXN1840 Trial Data in Wilson Disease", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/monopar-reports-publication-phase-2-215737651.html", "source_name": "MT Newswires", "published_at": "2026-05-19T21:57:37+00:00", "published_display": "19 May 2026 21:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/monopar-announces-publication-phase-2-213300471.html", "source_name": "GlobeNewswire", "published_at": "2026-05-19T21:33:00+00:00", "published_display": "19 May 2026 21:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/monopar-therapeutics-reports-first-quarter-180000306.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T18:00:00+00:00", "published_display": "14 May 2026 18:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Not Too Worried About Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxObGpBeC1ndXE4YzVwY3dYUEJOX3o2THdfYUtXSEc1cnoxcHdBTm8wOWFXaUhiQ2hzd1FtNXVPa0x2eG8tQkRjUHJNUFdtcHpvSEhKZTNvTWpUQ1VxWG12ankzeWhJdjBxRjZuMzlxNm80WlRmVTNwazJWOWxVNV95aW83U2pvQi1reV81UzhMR2xTUGFYMUt4b0VZb250TUgzeWxQVVNCSE00UEhVeHhhb1htczg4amdhUTlJblB0MUlIWDRpU19kMi1PbDF5dnVLdVZvSC1qS0h6R3UzQ1RiTnVMcFBScVNpX0s2d9IB8gFBVV95cUxOR1FBMWVTenJVYXZtZXN1aktlUkFzNmtsWjVXbHhidy10bjBPa0ZYbkxidnBIRGpEUTZXRGxNTnREci1sbUtMZWNQYmQwX3laQUZ6WGR6amU3T0NVR3o5MDNfZmhuTTQzdmxfUkcydGpWZWdsU2FPMzJaZC1xNWRzZ0NBT1F3d2dnTjkwSDZfYThPT2QtQmZKN1VOeDhZVHYwcHlhZ1FLUlhIQmVqWFhOSldQb0VqQjM0cTJGTm9sX0FWdkJoczFKVkZWTkNXVWd1bWE3VXdVUFNLVVRaYVltTk51YU5JN2JhZnViam1EbWlTZw?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOTV8wOFJ5eHFESG5Qd05OQWtFd3dWVTJJWlRMU3Z6THJWMVhZSllZYkhrOHJrS1Itd2tjejBkUXhzbWs4RWVFVXEtZ2dBU24ya1lTTEh0a0h2UDNRWi1OWDhXUWRLUXAzX2FrWUpZaDhiWDM4eTFaQVpZSGhranNxclpWYlJmSFppN3JRSHE2ZlJ0bFUyNUVtcHhZY3BOWDJ6YWp0Qw?oc=5", "source_name": "Market source", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/monopar-presents-phase-3-data-230000865.html", "source_name": "GlobeNewswire", "published_at": "2026-04-19T23:00:00+00:00", "published_display": "19 Apr 2026 23:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monopar Therapeutics Inc. Reports Q4 and Full-Year 2025 Financial Results and Highlights Progress for ALXN1840 in Wilson Disease | MNPR Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxPS2ZmcF9tNXlOb0xNWUtCMkZQSjVzUUlNWEhYUXpucm9ScWpESlBKNDFkRzhhX0pjQWJkTVU5UHVuT1dMYzBNclhpOUJIc3ZtUDNWV2dhaXpvZG1FRUNpTVBvSWxuWExDV3VBMFhPN3JBTHF1R2lrMXdjdnlraDE2SkNBUC01M2s0OVpzd2RRZWpZY3F4aVlCbk1yMEM0RFNHZkZnSkh6Rm5iRlllZ0VrX3FQdzVKbnB2a1lGQ0FXd1N4TEtqYnZSZWtGczNfNEZ0aGZUcnpPRTljS3JOcGwyeWM1ZkRLX1B4U2haM0FHLXlsWDQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 93, "total_relevant": 54, "sentiment_summary": {"positive": 12, "negative": 2, "neutral": 40, "score": 56, "total": 54, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 85, "events": [{"event": "general", "label": "Market update", "weight": 20.5, "count": 36}, {"event": "earnings", "label": "Earnings", "weight": 5.91, "count": 13}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 12, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 106.6, "latest_week": "2026-07-10", "one_week_move": 9.0, "four_week_move": 78.4, "twelve_week_move": 89.6, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.288249, "market_dynamics_buy_signal": false, "relative_strength": 42.457557, "fair_value_gap": 247.7, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 49.9573, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+9.0% over one week, +78.4% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 12}, {"label": "TradingView", "count": 9}, {"label": "Market source", "count": 8}, {"label": "GlobeNewswire", "count": 5}, {"label": "simplywall.st", "count": 3}, {"label": "Seeking Alpha", "count": 2}, {"label": "Stock Traders Daily", "count": 2}, {"label": "MT Newswires", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 45}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 36}, {"label": "Earnings", "count": 13}, {"label": "Balance sheet", "count": 2}, {"label": "Regulatory and legal", "count": 2}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "85/100 classification confidence."}, {"label": "Company focus", "value": "45", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+9.0% over one week, +78.4% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Monopar: A Rare Disease Asset With Heavy-Metal Upside (Initiating Buy)"}], "updated_at": "2026-07-18T03:15:12.809536+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}